Somnigroup cuts earnings outlook, shares fall 8% premarket

Somnigroup reduced its 2026 earnings forecast to $2.85-$2.95 per share, missing estimates. Shares fell 8% premarket. Q3 earnings of $1.04 per share and $2.35B revenue also missed expectations. North American and international sales declined. Adjusted EBITDA rose 6.8% but fell short of estimates.

Original reporting
Published Nov 9, 2026, 11:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 12:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SGI
Bearish
high confidence
Mentioned
$SGI
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SGIBearishHigh
01

Why it matters

The earnings outlook miss and pre‑market sell‑off suggest short‑term downside risk, while the company’s margin compression may raise concerns about profitability trends.

02

Market read

Guidance downgrade and immediate price drop make this a high‑actionability, negative‑sentiment event for SGI.

03

What to watch

Potential cost‑saving initiatives or pipeline developments not disclosed could mitigate earnings weakness.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Somnigroup reported Q3 adjusted EPS of $1.04, net sales of $2.35 B, and a 7% YoY earnings growth outlook, all below analyst expectations.

Company-level read

Ticker impact

$SGIBearishHigh confidence
Context

Somnigroup cut its full-year earnings outlook to $2.85‑$2.95 per share, below consensus, and shares fell 8% pre‑market.

Expected impact

downward pressure as investors price in lower earnings expectations

Evidence & confidence

The new EPS range misses consensus and the stock already slid 8% pre‑market, indicating market reaction.

Market effects

May weigh on the broader sleep‑aid/pharmaceutical sector as peers face earnings pressure.

Limited to U.S. markets where SGI trades.

Low; impact confined to company and sector.

Counterpoint

If the guidance cut reflects a temporary slowdown, the stock could rebound on longer‑term growth prospects.

Key entities

  • Somnigroup

    Pharmaceutical company providing sleep‑related treatments.

Related articles

$SGIMed

KeyBanc cuts Somnigroup stock price target on industry headwinds

KeyBanc reduced its price target on Somnigroup (NYSE:SGI) to $100 from $105, citing industry headwinds and near-term challenges, while maintaining an Overweight rating. The company lowered its 2026 EPS guidance due to industry trends and higher transportation costs. Somnigroup's Q3 results missed estimates, with adjusted earnings of $1.04 per share on revenue of $2.35 billion. The company's P/E ratio is 26.78, and its PEG ratio is 0.33, suggesting attractive value.

HighAI 8/10

Somnigroup sales hit record $2.35 billion as net income falls 7.8%

Somnigroup reported record Q3 revenue of $2.35B, up 10.8% YoY, driven by Leggett & Platt acquisition. Net income fell 7.8% to $163.5M, but adjusted net income rose 13.7% to $228.9M. Mattress Firm and international sales declined. CEO Scott Thompson highlighted the acquisition's strategic benefits. Full-year adjusted EPS guidance revised to $2.85-$2.95. Dividend of $0.17 per share declared.

$SGIHighAI 8/10

Somnigroup (SGI) Q3 2026 Earnings Call Transcript

Somnigroup (SGI) reported Q3 2026 net sales of $2.35B, up 10.8% YoY, driven by the Leggett & Platt acquisition. Adjusted EPS rose 9.5% to $1.04. However, adjusted gross margin declined to 43.0% due to the acquired business's product mix. Mattress Firm and Tempur Sealy units saw sales declines. Dreams unit faced operational disruptions, costing $50M in lost sales. Full-year guidance: net sales $8.65B, adjusted EPS $2.85-$2.95. Management plans store expansions and new product launches.

$SGIMedAI 8/10

Somnigroup International Inc (SGI) (Q3 2026) Earnings Call Highlights: Record Sales

Somnigroup International Inc (SGI) reported Q3 2026 record sales of $2.4B, adjusted EBITDA of $448M, and adjusted EPS of $1.04, up 10% YoY. Growth driven by Leggett & Platt acquisition and strong Stearns & Foster lineup. Challenges include a 35% sales decline at Dreams due to ERP disruptions and softer global bedding industry. SGI expects $125M in synergies in 2027. CEO outlined EPS growth targets, citing Leggett accretion and synergies.

$SGIMed

Somnigroup International Q3 Earnings Call Highlights

Somnigroup International (NYSE:SGI) reported Q3 sales decline of 12% due to Dreams disruption, with operating margin falling to 9.4%. Mattress Firm sales were $1 billion, with same-store sales down 2%. The company expects full-year adjusted earnings of $2.85-$2.95 per share. Plans include a multiyear store expansion and new product launches.